The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
|
|---|---|
| Published in |
Frontiers in Pharmacology, August 2018
|
| DOI | 10.3389/fphar.2018.00874 |
| Pubmed ID | |
| Authors |
Simona Sestito, Massimiliano Runfola, Marco Tonelli, Grazia Chiellini, Simona Rapposelli |
| Abstract |
Glioblastoma multiforme (GBM) is the most common tumor of the CNS, and the deadliest form of brain cancer. The rapid progression, the anatomic location in the brain and a deficient knowledge of the pathophysiology, often limit the effectiveness of therapeutic interventions. Current pillars of GBM therapies include surgical resection, radiotherapy and chemotherapy, but the low survival rate and the short life expectation following these treatments strongly underline the urgency to identify innovative and more effective therapeutic tools. Frequently, patients subjected to a mono-target therapy, such as Temozolomide (TMZ), develop drug resistance and undergo relapse, indicating that targeting a single cellular node is not sufficient for eradication of this disease. In this context, a multi-targeted therapeutic approach aimed at using compounds, alone or in combination, capable of inhibiting more than one specific molecular target, offers a promising alternative. Such strategies have already been well integrated into drug discovery campaigns, including in the field of anticancer drugs. In this miniperspective, we will discuss the recent progress in the treatment of GBM focusing on innovative and effective preclinical strategies, which are based on a multi-targeted approach. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 19% |
| Researcher | 7 | 13% |
| Student > Ph. D. Student | 7 | 13% |
| Student > Bachelor | 4 | 8% |
| Unspecified | 3 | 6% |
| Other | 6 | 11% |
| Unknown | 16 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 17% |
| Biochemistry, Genetics and Molecular Biology | 8 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Neuroscience | 5 | 9% |
| Agricultural and Biological Sciences | 3 | 6% |
| Other | 8 | 15% |
| Unknown | 14 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2018.
All research outputs
#14,359,953
of 23,100,534 outputs
Outputs from Frontiers in Pharmacology
#4,733
of 16,457 outputs
Outputs of similar age
#184,952
of 331,039 outputs
Outputs of similar age from Frontiers in Pharmacology
#114
of 382 outputs
Altmetric has tracked 23,100,534 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,457 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,039 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 382 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.